CAS: 456-04-2; 2-Chloro-1-(4-Fluorophenyl)Ethanone

上下游产品

fluorobenzene chloroacetyl chloride 1-(4-fluorophenyl)ethanone 1-ethynyl-4-fluorobenzene 4-(4-fluorophenyl)-2-methylthiazole 1-(4-fluorophenyl)-2-(4-methoxyphenyl)ethan-1-one 1-(4-fluoro-phenyl)-1,2-bis-(4-methoxy-phenyl)-ethanol 4,4'-difluorodeoxybenzoin

4-氟苯乙烯置于magnesium(II) Chloride Hexahydrate,Cobalt(II) Chloride Hexahydrate,氧气,Lithium Perchlorate体系中,用 二氯甲烷,丙酮 作为反应溶剂,化学反应 10.0H,以62%的收率获得产物2-氯代-4'-氟苯乙酮
参考文献:Cv驱动的优化:通过orr进行烯烃催化钴催化的电化学氧化法
标题:Cv驱动的优化:通过orr进行烯烃催化钴催化的电化学氧化法
摘要:代替通过基于产率的化学试验和错误筛选反应条件,基于电位的循环伏安法可替代地用于优化烯烃的电化学氧氯化反应.通过这种非常规的筛选方法,可以以合理,省时和节能的方式识别出包括催化剂,氯离子源和溶剂的摩尔比在内的催化剂体系.最佳的催化系统与氧还原反应相结合,可以利用持久的自由基效应,为所需的转化提供广阔的底物范围.紫外可见和cv滴定实验证实了原位形成的催化物质[cocl 5].此外,循环伏安法被用于在我们的反应系统中获得机理的见解.
DOI:10.1002/adsc.201901260

专利信息

专利号:US-4739073-A
优先权日:1983-11-04
标题:Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
发明人：KATHAWALA FAIZULLA G
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Compounds of the formula wherein one of R and Ro is and the other is primary or secondary C1-6alkyl not containing an asymmetric carbon atom, C3-6cycloalkyl or phenyl(CH2)m-, wherein R4 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5a is hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R5 and R5a must be hydrogen when R4 is hydrogen, R5a must be hydrogen when R5 is hydrogen, not more than one of R4 and R5 is trifluoromethyl, not more than one of R4 and R5 is phenoxy, and not more than one of R4 and R5 is benzyloxy, R2 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C3-6cycloalkyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R3 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R3 must be hydrogen when R2 is hydrogen, not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, and not more than one of R2 and R3 is benzyloxy, X is -(CH2)n- or -CH=CH-, wherein n is 0, 1, 2 or 3, and Z is wherein R6 is hydrogen or C1-3alkyl, and R7 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, benzyl or M, wherein M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

专利号:US-5354772-A
优先权日:1982-11-22
标 题:Indole analogs of mevalonolactone and derivatives thereof
发明人：KATHAWALA FAIZULLA G
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Compounds of the formula wherein one of R and Ro is and the other is primary or secondary C1-6alkyl not containing an asymmetric carbon atom, C3-6cycloalkyl or phenyl-(CH2)m-, wherein R4 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5a is hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R5 and R5a must be hydrogen when R4 is hydrogen, R5a must be hydrogen when R5 is hydrogen, not more than one of R4 and R5 is trifluoromethyl, not more than one of R4 and R5 is phenoxy, and not more than one of R4 and R5 is benzyloxy, R2 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C3-6cycloalkyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R3 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R3 must be hydrogen when R2 is hydrogen, not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, and not more than one of R2 and R3 is benzyloxy, X is -(CH2)n- or -CH=CH-, wherein n is 0, 1, 2 or 3, and Z is wherein R6 is hydrogen or C1-3alkyl, and R7 is hydrogen, R7b or M, wherein R7b is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and therefore, in the treatment of hyperliopoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

专利号:EP-2086952-A2
优先权日:2006-11-30
标题 :Method for the stereoselective synthesis of chiral epoxides by adh reduction of ketones substituted with alpha starting groups and cyclisation

专利号:US-5929075-A
优先权日:1994-10-27
标 题:Apolipoprotein-B synthesis inhibitors
发明人：HEERES JAN; BACKX LEO JACOBUS JOZEF; HENDRICKX ROBERT JOZEF MARIA; VAN DER EYCKEN LUC ALFONS LEO; DE CHAFFOY DE COURCELLES DIDIE
权利人:JANSSEN PHARMACEUTICA NV
摘要:The present invention provides novel compounds of formula ##STR1## the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts thereof, wherein A and B taken together form a bivalent radical of formula: n --Nâ•?CH-- (a), --CHâ•?N-- (b), --CH 2 --CH 2 -- (c), --CHâ•?CH-- (d), --C(â•?O)--CH 2 -- (e), --CH 2 --C(â•?O)-- (f); R 1 is hydrogen, C 1-6 alkyl, or halo; R 2 is hydrogen or halo; R 3 is hydrogen; C 1-8 alkyl; C 3-6 cycloalkyl or C 1-8 alkyl substituted with hydroxy, oxo, C 3-6 cycloalkyl or aryl. Het is five- or six-membered optionally substituted heterocyclic ring. The use as a medicine, especially as a lipid lowering agent is disclosed as well as pharmaceutical compositions and processes for preparing compounds and compositions.

专利号:DE-102006056526-A1
优先权日:2006-11-30
标题:Process for the stereoselective synthesis of chiral epoxides by ADH reduction of alpha-leaving group-substituted ketones and cyclization

专利号:WO-2008064817-A2
优先权日:2006-11-30
标 题 :Method for the stereoselective synthesis of chiral epoxides by adh reduction of ketones substituted with alpha starting groups and cyclisation